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Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States, 2017
U.S. Department of Health and Human Services
Centers for Disease Control and Prevention
In February 2017, the Recommended Immunization Schedule for Adults Aged 19 Years or Older, 
United States, 2017 became effective, as recommended by the Advisory Committee on 
Immunization Practices (ACIP) and approved by the Centers for Disease Control and Prevention 
(CDC). The 2017 adult immunization schedule was also reviewed and approved by the following 
professional medical organizations:
• American College of Physicians (www.acponline.org)
• American Academy of Family Physicians (www.aafp.org)
• American College of Obstetricians and Gynecologists (www.acog.org)
• American College of Nurse-Midwives (www.midwife.org)
CDC announced the availability of the 2017 adult immunization schedule at www.cdc.gov/
vaccines/schedules/hcp/index.html in the Morbidity and Mortality Weekly Report (MMWR).1 The 
schedule is published in its entirety in the Annals of Internal Medicine.2
The adult immunization schedule describes the age groups and medical conditions and other 
indications for which licensed vaccines are recommended. The 2017 adult immunization schedule 
consists of:
• Figure 1. Recommended immunization schedule for adults by age group
• Figure 2. Recommended immunization schedule for adults by medical condition and other 
indications
• Footnotes that accompany each vaccine containing important general information and 
considerations for special populations
• Table. Contraindications and precautions for vaccines routinely recommended for adults
Consider the following information when reviewing the adult immunization schedule:
• The figures in the adult immunization schedule should be read with the footnotes that 
contain important general information and information about vaccination of special 
populations.
• When indicated, administer recommended vaccines to adults whose vaccination history is 
incomplete or unknown.
• Increased interval between doses of a multi-dose vaccine does not diminish vaccine 
effectiveness; therefore, it is not necessary to restart the vaccine series or add doses to the 
series because of an extended interval between doses.
• Adults with immunocompromising conditions should generally avoid live vaccines, 
e.g., measles, mumps, and rubella vaccine. Inactivated vaccines, e.g., pneumococcal or 
inactivated influenza vaccines, are generally acceptable.
• Combination vaccines may be used when any component of the combination is indicated 
and when the other components of the combination vaccine are not contraindicated. 
• The use of trade names in the adult immunization schedule is for identification purposes 
only and does not imply endorsement by the ACIP or CDC.
Details on vaccines recommended for adults and complete ACIP statements are available at www.
cdc.gov/vaccines/hcp/acip-recs/index.html. Additional CDC resources include: 
• A summary of information on vaccination recommendations, vaccination of persons 
with immunodeficiencies, preventing and managing adverse reactions, vaccination 
contraindications and precautions, and other information can be found in General 
Recommendations on Immunization at www.cdc.gov/mmwr/preview/mmwrhtml/rr6002a1.htm.
• Vaccine Information Statements that explain benefits and risks of vaccines are available at 
www.cdc.gov/vaccines/hcp/vis/index.html.
• Information and resources regarding vaccination of pregnant women are available at www.
cdc.gov/vaccines/adults/rec-vac/pregnant.html.
• Information on travel vaccine requirements and recommendations is available at  
wwwnc.cdc.gov/travel/destinations/list.
• CDC Vaccine Schedules App for clinicians and other immunization service providers to 
download is available at www.cdc.gov/vaccines/schedules/hcp/schedule-app.html.
• Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger is 
available at www.cdc.gov/vaccines/schedules/hcp/index.html.
Report suspected cases of reportable vaccine-preventable diseases to the local or state health 
department.
Report all clinically significant post-vaccination reactions to the Vaccine Adverse Event Reporting 
System at www.vaers.hhs.gov or by telephone, 800-822-7967. All vaccines included in the 2017 
adult immunization schedule except herpes zoster and 23-valent pneumococcal polysaccharide 
vaccines are covered by the Vaccine Injury Compensation Program. Information on how to file a 
vaccine injury claim is available at www.hrsa.gov/vaccinecompensation or by telephone, 800-338-
2382.
Submit questions and comments regarding the 2017 adult immunization schedule to CDC 
through www.cdc.gov/cdc-info or by telephone, 800-CDC-INFO (800-232-4636), in English and 
Spanish, 8:00am–8:00pm ET, Monday–Friday, excluding holidays.
The following acronyms are used for vaccines recommended for adults:
HepA hepatitis A vaccine
HepA-HepB hepatitis A and hepatitis B vaccines
HepB hepatitis B vaccine
Hib  Haemophilus influenzae type b conjugate vaccine
HPV vaccine human papillomavirus vaccine
HZV herpes zoster vaccine
IIV inactivated influenza vaccine
LAIV live attenuated influenza vaccine
MenACWY serogroups A, C, W, and Y meningococcal conjugate vaccine
MenB  serogroup B meningococcal vaccine
MMR  measles, mumps, and rubella vaccine
MPSV4  serogroups A, C, W, and Y meningococcal polysaccharide vaccine
PCV13  13-valent pneumococcal conjugate vaccine 
PPSV23  23-valent pneumococcal polysaccharide vaccine
RIV recombinant influenza vaccine
Td  tetanus and diphtheria toxoids
Tdap  tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine
VAR varicella vaccine
1 MMWR Morb Mortal Wkly Rep. 2017;66(5). Available at www.cdc.gov/mmwr/volumes/66/wr/mm6605e2.htm?s_
cid=mm6605e2_w. 
2 Ann Intern Med. 2017;166:209-218. Available at annals.org/aim/article/doi/10.7326/M16-2936.
Figure 1. Recommended immunization schedule for adults aged 19 years or older by age group, United States, 2017






















1 or 2 doses depending on indication
Substitute Tdap for Td once, then Td booster every 10 yrs
1 or 2 doses depending on indication
2 or 3 doses depending on vaccine
3 doses
2 doses
1 or more doses depending on indication
2 or 3 doses depending on vaccine
1 or 3 doses depending on indication
Recommended for adults who meet the  
age requirement, lack documentation of 
vaccination, or lack evidence of past infection
Recommended for adults with additional 
medical conditions or other indications No recommendation
















































3 doses  
post-HSCT  
recipients only
Recommended for adults who meet the  
age requirement, lack documentation of 
vaccination, or lack evidence of past infection
Recommended for adults with additional 
medical conditions or other indications Contraindicated No recommendation
3 doses
2 or 3 doses depending on vaccine
1 dose
1 dose
1, 2, or 3 doses depending on indication
2 or 3 doses depending on vaccine
1 or more doses depending on indication





1 or 2 doses depending on indication
3 doses through age 26 yrs
2 doses
3 doses through age 26 yrs
1 dose annually
Substitute Tdap for Td once, then Td booster every 10 yrs
Footnotes. Recommended immunization schedule for adults aged 19 years or older, United States, 2017
1. Influenza vaccination
General information
• All persons aged 6 months or older who do not have a 
contraindication should receive annual influenza vaccination with an 
age-appropriate formulation of inactivated influenza vaccine (IIV) or 
recombinant influenza vaccine (RIV).
• In addition to standard-dose IIV, available options for adults in 
specific age groups include: high-dose or adjuvanted IIV for adults 
aged 65 years or older, intradermal IIV for adults aged 18 through 64 
years, and RIV for adults aged 18 years or older.
• Notes: Live attenuated influenza vaccine (LAIV) should not be used 
during the 2016–2017 influenza season. A list of currently available 
influenza vaccines is available at www.cdc.gov/flu/protect/vaccine/
vaccines.htm.
Special populations
• Adults with a history of egg allergy who have only hives after 
exposure to egg should receive age-appropriate IIV or RIV.
• Adults with a history of egg allergy other than hives, e.g., 
angioedema, respiratory distress, lightheadedness, or recurrent 
emesis, or who required epinephrine or another emergency medical 
intervention, may receive age-appropriate IIV or RIV. The selected 
vaccine should be administered in an inpatient or outpatient 
medical setting and under the supervision of a healthcare provider 
who is able to recognize and manage severe allergic conditions.
• Pregnant women and women who might become pregnant in the 
upcoming influenza season should receive IIV.
2. Tetanus, diphtheria, and acellular pertussis vaccination
General information
• Adults who have not received tetanus and diphtheria toxoids and 
acellular pertussis vaccine (Tdap) or for whom pertussis vaccination 
status is unknown should receive 1 dose of Tdap followed by a 
tetanus and diphtheria toxoids (Td) booster every 10 years. Tdap 
should be administered regardless of when a tetanus or diphtheria 
toxoid-containing vaccine was last received.
• Adults with an unknown or incomplete history of a 3-dose primary 
series with tetanus and diphtheria toxoid-containing vaccines 
should complete the primary series that includes 1 dose of Tdap. 
Unvaccinated adults should receive the first 2 doses at least 4 weeks 
apart and the third dose 6–12 months after the second dose.
• Notes: Information on the use of Td or Tdap as tetanus prophylaxis in 
wound management is available at www.cdc.gov/mmwr/preview/
mmwrhtml/rr5517a1.htm.
Special populations
• Pregnant women should receive 1 dose of Tdap during each 
pregnancy, preferably during the early part of gestational weeks 
27–36, regardless of prior history of receiving Tdap.
3. Measles, mumps, and rubella vaccination
General information
• Adults born in 1957 or later without acceptable evidence of 
immunity to measles, mumps, or rubella (defined below) should 
receive 1 dose of measles, mumps, and rubella vaccine (MMR) unless 
they have a medical contraindication to the vaccine, e.g., pregnancy 
or severe immunodeficiency.
• Notes: Acceptable evidence of immunity to measles, mumps, or 
rubella in adults is: born before 1957, documentation of receipt of 
MMR, or laboratory evidence of immunity or disease. Documentation 
of healthcare provider-diagnosed disease without laboratory 
confirmation is not acceptable evidence of immunity.
Special populations
• Pregnant women who do not have evidence of immunity to rubella 
should receive 1 dose of MMR upon completion or termination of 
pregnancy and before discharge from the healthcare facility; non-
pregnant women of childbearing age without evidence of rubella 
immunity should receive 1 dose of MMR.
• Adults with primary or acquired immunodeficiency including malignant 
conditions affecting the bone marrow or lymphatic system, systemic 
immunosuppressive therapy, or cellular immunodeficiency should not 
receive MMR.
• Adults with human immunodeficiency virus (HIV) infection and CD4+ 
T-lymphocyte count ≥200 cells/μl for at least 6 months who do not have 
evidence of measles, mumps, or rubella immunity should receive 2 
doses of MMR at least 28 days apart. Adults with HIV infection and CD4+ 
T-lymphocyte count <200 cells/μl should not receive MMR.
• Adults who work in healthcare facilities should receive 2 doses of MMR 
at least 28 days apart; healthcare personnel born before 1957 who are 
unvaccinated or lack laboratory evidence of measles, mumps, or rubella 
immunity, or laboratory confirmation of disease should be considered 
for vaccination with 2 doses of MMR at least 28 days apart for measles or 
mumps, or 1 dose of MMR for rubella.
• Adults who are students in postsecondary educational institutions or 
plan to travel internationally should receive 2 doses of MMR at least 28 
days apart.
• Adults who received inactivated (killed) measles vaccine or measles 
vaccine of unknown type during years 1963–1967 should be 
revaccinated with 1 or 2 doses of MMR.
• Adults who were vaccinated before 1979 with either inactivated mumps 
vaccine or mumps vaccine of unknown type who are at high risk for 
mumps infection, e.g., work in a healthcare facility, should be considered 
for revaccination with 2 doses of MMR at least 28 days apart.
4. Varicella vaccination
General information
• Adults without evidence of immunity to varicella (defined below) should 
receive 2 doses of single-antigen varicella vaccine (VAR) 4–8 weeks apart, 
or a second dose if they have received only 1 dose.
• Persons without evidence of immunity for whom VAR should be 
emphasized are: adults who have close contact with persons at high 
risk for serious complications, e.g., healthcare personnel and household 
contacts of immunocompromised persons; adults who live or work in 
an environment in which transmission of varicella zoster virus is likely, 
e.g., teachers, childcare workers, and residents and staff in institutional 
settings; adults who live or work in environments in which varicella 
transmission has been reported, e.g., college students, residents and 
staff members of correctional institutions, and military personnel; non-
pregnant women of childbearing age; adolescents and adults living in 
households with children; and international travelers.
• Notes: Evidence of immunity to varicella in adults is: U.S.-born before 
1980 (for pregnant women and healthcare personnel, U.S.-born before 
1980 is not considered evidence of immunity); documentation of 2 
doses of VAR at least 4 weeks apart; history of varicella or herpes zoster 
diagnosis or verification of varicella or herpes zoster disease by a 
healthcare provider; or laboratory evidence of immunity or disease.
Special populations
• Pregnant women should be assessed for evidence of varicella immunity. 
Pregnant women who do not have evidence of immunity should receive 
the first dose of VAR upon completion or termination of pregnancy and 
before discharge from the healthcare facility, and the second dose 4–8 
weeks after the first dose.
• Healthcare institutions should assess and ensure that all healthcare 
personnel have evidence of immunity to varicella.
• Adults with malignant conditions, including those that affect 
the bone marrow or lymphatic system or who receive systemic 
immunosuppressive therapy, should not receive VAR.
• Adults with human immunodeficiency virus (HIV) infection and CD4+ 
T-lymphocyte count ≥200 cells/μl may receive 2 doses of VAR 3 months 
apart. Adults with HIV infection and CD4+ T-lymphocyte count <200 
cells/μl should not receive VAR.
5. Herpes zoster vaccination
General information
• Adults aged 60 years or older should receive 1 dose of herpes zoster 
vaccine (HZV), regardless of whether they had a prior episode of herpes 
zoster.
Special populations
• Adults aged 60 years or older with chronic medical conditions may 
receive HZV unless they have a medical contraindication, e.g., pregnancy 
or severe immunodeficiency.
• Adults with malignant conditions, including those that affect 
the bone marrow or lymphatic system or who receive systemic 
immunosuppressive therapy, should not receive HZV.
• Adults with human immunodeficiency virus (HIV) infection and CD4+ 
T-lymphocyte count <200 cells/μl should not receive HZV.
6. Human papillomavirus vaccination
General information
• Adult females through age 26 years and adult males through age 21 
years who have not received any human papillomavirus (HPV) vaccine 
should receive a 3-dose series of HPV vaccine at 0, 1-2, and 6 months. 
Males aged 22 through 26 years may be vaccinated with a 3-dose series 
of HPV vaccine at 0, 1–2, and 6 months.
• Adult females through age 26 years and adult males through age 
21 years (and males aged 22 through 26 years who may receive HPV 
vaccination) who initiated the HPV vaccination series before age 15 years 
and received 2 doses at least 5 months apart are considered adequately 
vaccinated and do not need an additional dose of HPV vaccine.
• Adult females through age 26 years and adult males through age 
21 years (and males aged 22 through 26 years who may receive HPV 
vaccination) who initiated the HPV vaccination series before age 15 years 
and received only 1 dose, or 2 doses less than 5 months apart, are not 
considered adequately vaccinated and should receive 1 additional dose 
of HPV vaccine.
• Notes: HPV vaccination is routinely recommended for children at age 11 
or 12 years. For adults who had initiated but did not complete the HPV 
vaccination series, consider their age at first HPV vaccination (described 
above) and other factors (described below) to determine if they have 
been adequately vaccinated.
Special populations
• Men who have sex with men through age 26 years who have not 
received any HPV vaccine should receive a 3-dose series of HPV vaccine 
at 0, 1-2, and 6 months. 
• Adult females and males through age 26 years with 
immunocompromising conditions (described below), including those 
with human immunodeficiency virus (HIV) infection, should receive a 
3-dose series of HPV vaccine at 0, 1–2, and 6 months.
• Pregnant women are not recommended to receive HPV vaccine, 
although there is no evidence that the vaccine poses harm. If a woman 
is found to be pregnant after initiating the HPV vaccination series, delay 
the remaining doses until after the pregnancy. No other intervention 
is needed. Pregnancy testing is not needed before administering HPV 
vaccine.
• Notes: Immunocompromising conditions for which a 3-dose series of 
HPV vaccine is indicated are primary or secondary immunocompromising 
conditions that might reduce cell-mediated or humoral immunity, e.g., 
B-lymphocyte antibody deficiencies, complete or partial T-lymphocyte 
defects, HIV infection, malignant neoplasm, transplantation, autoimmune 
disease, and immunosuppressive therapy.
7. Pneumococcal vaccination
General information
• Adults who are immunocompetent and aged 65 years or older should 
receive 13-valent pneumococcal conjugate vaccine (PCV13) followed by 
23-valent pneumococcal polysaccharide vaccine (PPSV23) at least 1 year 
after PCV13.
• Notes: Adults are recommended to receive 1 dose of PCV13 and 1, 2, 
or 3 doses of PPSV23 depending on indication. When both PCV13 and 
PPSV23 are indicated, PCV13 should be administered first; PCV13 and 
PPSV23 should not be administered during the same visit. If PPSV23 has 
previously been administered, PCV13 should be administered at least 1 
year after PPSV23. When two or more doses of PPSV23 are indicated, the 
interval between PPSV23 doses should be at least 5 years. Supplemental 
information on pneumococcal vaccine timing for adults aged 65 years 
or older and adults aged 19 years or older at high risk for pneumococcal 
disease (described below) is available at www.cdc.gov/vaccines/vpd-vac/
pneumo/downloads/adult-vax-clinician-aid.pdf. No additional doses of 
PPSV23 are indicated for adults who received PPSV23 at age 65 years 
or older. When indicated, PCV13 and PPSV23 should be administered 
to adults whose pneumococcal vaccination history is incomplete or 
unknown.
Special populations
• Adults aged 19 through 64 years with chronic heart disease including 
congestive heart failure and cardiomyopathies (excluding hypertension); 
chronic lung disease including chronic obstructive lung disease, 
emphysema, and asthma; chronic liver disease including cirrhosis; 
alcoholism; or diabetes mellitus; or who smoke cigarettes should receive 
PPSV23. At age 65 years or older, they should receive PCV13 and another 
dose of PPSV23 at least 1 year after PCV13 and at least 5 years after the 
most recent dose of PPSV23.
• Adults aged 19 years or older with immunocompromising conditions or 
anatomical or functional asplenia (described below) should receive PCV13 
and a dose of PPSV23 at least 8 weeks after PCV13, followed by a second 
dose of PPSV23 at least 5 years after the first dose of PPSV23. If the most 
recent dose of PPSV23 was administered before age 65 years, at age 65 
years or older, administer another dose of PPSV23 at least 8 weeks after 
PCV13 and at least 5 years after the most recent dose of PPSV23.
• Adults aged 19 years or older with cerebrospinal fluid leak or cochlear 
implant should receive PCV13 followed by PPSV23 at least 8 weeks after 
PCV13. If the most recent dose of PPSV23 was administered before age 
65 years, at age 65 years or older, administer another dose of PPSV23 at 
least 8 weeks after PCV13 and at least 5 years after the most recent dose 
of PPSV23.
• Notes: Immunocompromising conditions that are indications for 
pneumococcal vaccination are congenital or acquired immunodeficiency 
including B- or T-lymphocyte deficiency, complement deficiencies, 
and phagocytic disorders excluding chronic granulomatous disease; 
human immunodeficiency virus (HIV) infection; chronic renal failure 
and nephrotic syndrome; leukemia, lymphoma, Hodgkin disease, 
generalized malignancy, and multiple myeloma; solid organ transplant; 
and iatrogenic immunosuppression including long-term systemic 
corticosteroid and radiation therapy. Anatomical or functional asplenia 
that are indications for pneumococcal vaccination are sickle cell disease 
and other hemoglobinopathies, congenital or acquired asplenia, splenic 
dysfunction, and splenectomy. Pneumococcal vaccines should be given 
at least 2 weeks before immunosuppressive therapy or an elective 
splenectomy, and as soon as possible to adults who are diagnosed with 
HIV infection.
8. Hepatitis A vaccination
General information
• Adults who seek protection from hepatitis A virus infection may receive 
a 2-dose series of single antigen hepatitis A vaccine (HepA) at either 0 
and 6–12 months (Havrix) or 0 and 6–18 months (Vaqta). Adults may 
also receive a combined hepatitis A and hepatitis B vaccine (HepA-HepB) 
(Twinrix) as a 3-dose series at 0, 1, and 6 months. Acknowledgment of a 
specific risk factor by those who seek protection is not needed.
Special populations
• Adults with any of the following indications should receive a HepA 
series: have chronic liver disease, receive clotting factor concentrates, 
men who have sex with men, use injection or non-injection drugs, 
or work with hepatitis A virus-infected primates or in a hepatitis A 
research laboratory setting.
• Adults who travel in countries with high or intermediate levels of 
endemic hepatitis A infection or anticipate close personal contact 
with an international adoptee, e.g., reside in the same household or 
regularly babysit, from a country with high or intermediate level of 
endemic hepatitis A infection within the first 60 days of arrival in the 
United States should receive a HepA series.
9. Hepatitis B vaccination
General information
• Adults who seek protection from hepatitis B virus infection may 
receive a 3-dose series of single-antigen hepatitis B vaccine (HepB) 
(Engerix-B, Recombivax HB) at 0, 1, and 6 months. Adults may also 
receive a combined hepatitis A and hepatitis B vaccine (HepA-HepB) 
(Twinrix) at 0, 1, and 6 months. Acknowledgment of a specific risk 
factor by those who seek protection is not needed.
Special populations
• Adults at risk for hepatitis B virus infection by sexual exposure should 
receive a HepB series, including sex partners of hepatitis B surface 
antigen (HBsAg)-positive persons, sexually active persons who 
are not in a mutually monogamous relationship, persons seeking 
evaluation or treatment for a sexually transmitted infection, and men 
who have sex with men (MSM).
• Adults at risk for hepatitis B virus infection by percutaneous or 
mucosal exposure to blood should receive a HepB series, including 
adults who are recent or current users of injection drugs, household 
contacts of HBsAg-positive persons, residents and staff of facilities 
for developmentally disabled persons, incarcerated, healthcare 
and public safety workers at risk for exposure to blood or blood-
contaminated body fluids, younger than age 60 years with diabetes 
mellitus, and age 60 years or older with diabetes mellitus at the 
discretion of the treating clinician.
• Adults with chronic liver disease including, but not limited to, 
hepatitis C virus infection, cirrhosis, fatty liver disease, alcoholic liver 
disease, autoimmune hepatitis, and an alanine aminotransferase 
(ALT) or aspartate aminotransferase (AST) level greater than twice 
the upper limit of normal should receive a HepB series.
• Adults with end-stage renal disease including those on pre-dialysis 
care, hemodialysis, peritoneal dialysis, and home dialysis should 
receive a HepB series. Adults on hemodialysis should receive a 
3-dose series of 40 µg Recombivax HB at 0, 1, and 6 months or a 
4-dose series of 40 µg Engerix-B at 0, 1, 2, and 6 months.
• Adults with human immunodeficiency virus (HIV) infection should 
receive a HepB series.
• Pregnant women who are at risk for hepatitis B virus infection 
during pregnancy, e.g., having more than one sex partner during 
the previous six months, been evaluated or treated for a sexually 
transmitted infection, recent or current injection drug use, or had an 
HBsAg-positive sex partner, should receive a HepB series.
• International travelers to regions with high or intermediate levels of 
endemic hepatitis B virus infection should receive a HepB series.
• Adults in the following settings are assumed to be at risk for 
hepatitis B virus infection and should receive a HepB series: sexually 
transmitted disease treatment facilities, HIV testing and treatment 
facilities, facilities providing drug-abuse treatment and prevention 
services, healthcare settings targeting services to persons who 
inject drugs, correctional facilities, healthcare settings targeting 
services to MSM, hemodialysis facilities and end-stage renal disease 




• Adults with anatomical or functional asplenia or persistent complement 
component deficiencies should receive a 2-dose primary series of 
serogroups A, C, W, and Y meningococcal conjugate vaccine (MenACWY) 
at least 2 months apart and revaccinate every 5 years. They should also 
receive a series of serogroup B meningococcal vaccine (MenB) with either 
a 2-dose series of MenB-4C (Bexsero) at least 1 month apart or a 3-dose 
series of MenB-FHbp (Trumenba) at 0, 1–2, and 6 months.
• Adults with human immunodeficiency virus (HIV) infection who have 
not been previously vaccinated should receive a 2-dose primary series of 
MenACWY at least 2 months apart and revaccinate every 5 years. Those 
who previously received 1 dose of MenACWY should receive a second 
dose at least 2 months after the first dose. Adults with HIV infection are 
not routinely recommended to receive MenB because meningococcal 
disease in this population is caused primarily by serogroups C, W, and Y.
• Microbiologists who are routinely exposed to isolates of Neisseria 
meningitidis should receive 1 dose of MenACWY and revaccinate every 5 
years if the risk for infection remains, and either a 2-dose series of MenB-
4C at least 1 month apart or a 3-dose series of MenB-FHbp at 0, 1–2, and 
6 months.
• Adults at risk because of a meningococcal disease outbreak should 
receive 1 dose of MenACWY if the outbreak is attributable to serogroup 
A, C, W, or Y, or either a 2-dose series of MenB-4C at least 1 month apart or 
a 3-dose series of MenB-FHbp at 0, 1–2, and 6 months if the outbreak is 
attributable to serogroup B.
• Adults who travel to or live in countries with hyperendemic or epidemic 
meningococcal disease should receive 1 dose of MenACWY and 
revaccinate every 5 years if the risk for infection remains. MenB is not 
routinely indicated because meningococcal disease in these countries is 
generally not caused by serogroup B.
• Military recruits should receive 1 dose of MenACWY and revaccinate 
every 5 years if the increased risk for infection remains.
• First-year college students aged 21 years or younger who live in 
residence halls should receive 1 dose of MenACWY if they have not 
received MenACWY at age 16 years or older.
• Young adults aged 16 through 23 years (preferred age range is 16 
through 18 years) who are healthy and not at increased risk for serogroup 
B meningococcal disease (described above) may receive either a 2-dose 
series of MenB-4C at least 1 month apart or a 2-dose series of MenB-
FHbp at 0 and 6 months for short-term protection against most strains of 
serogroup B meningococcal disease. 
• For adults aged 56 years or older who have not previously received 
serogroups A, C, W, and Y meningococcal vaccine and need only 1 
dose, meningococcal polysaccharide serogroups A, C, W, and Y vaccine 
(MPSV4) is preferred. For adults who previously received MenACWY 
or anticipate receiving multiple doses of serogroups A, C, W, and Y 
meningococcal vaccine, MenACWY is preferred. 
• Notes: MenB-4C and MenB-FHbp are not interchangeable, i.e., the same 
vaccine should be used for all doses to complete the series. There is no 
recommendation for MenB revaccination at this time. MenB may be 
administered at the same time as MenACWY but at a different anatomic 
site, if feasible.
11.  Haemophilus influenzae type b vaccination
Special populations
• Adults who have anatomical or functional asplenia or sickle cell disease, 
or are undergoing elective splenectomy should receive 1 dose of 
Haemophilus influenzae type b conjugate vaccine (Hib) if they have not 
previously received Hib. Hib should be administered at least 14 days 
before splenectomy.
• Adults with a hematopoietic stem cell transplant (HSCT) should receive 
3 doses of Hib in at least 4 week intervals 6–12 months after transplant 
regardless of their Hib history.
• Notes: Hib is not routinely recommended for adults with human 
immunodeficiency virus infection because their risk for Haemophilus 
influenzae type b infection is low.
Vaccine Additional Contraindications Additional Precautions
IIV1 • History of Guillain-Barré Syndrome within 6 weeks after previous influenza vaccination
• Egg allergy other than hives, e.g., angioedema, respiratory distress, lightheadedness, or recurrent emesis; 
or required epinephrine or another emergency medical intervention (IIV may be administered in an 
inpatient or outpatient medical setting and under the supervision of a healthcare provider who is able to 
recognize and manage severe allergic conditions)
RIV1 • History of Guillain-Barré Syndrome within 6 weeks after previous influenza vaccination
LAIV1 • LAIV should not be used during 2016–2017 influenza season • LAIV should not be used during 2016–2017 influenza season
Tdap/Td • For pertussis-containing vaccines: encephalopathy, e.g., coma, decreased level of consciousness, or 
prolonged seizures, not attributable to another identifiable cause within 7 days of administration of a 
previous dose of a vaccine containing tetanus or diphtheria toxoid or acellular pertussis
• Guillain-Barré Syndrome within 6 weeks after a previous dose of tetanus toxoid-containing vaccine
• History of Arthus-type hypersensitivity reactions after a previous dose of tetanus or diphtheria toxoid-
containing vaccine. Defer vaccination until at least 10 years have elapsed since the last tetanus toxoid-
containing vaccine
• For pertussis-containing vaccine, progressive or unstable neurologic disorder, uncontrolled seizures, 
or progressive encephalopathy (until a treatment regimen has been established and the condition has 
stabilized)
MMR2 • Severe immunodeficiency, e.g., hematologic and solid tumors, chemotherapy, congenital 
immunodeficiency or long-term immunosuppressive therapy3, human immunodeficiency virus (HIV) 
infection with severe immunocompromise
• Pregnancy
• Recent (within 11 months) receipt of antibody-containing blood product (specific interval depends on 
product)4
• History of thrombocytopenia or thrombocytopenic purpura
• Need for tuberculin skin testing5
VAR2 • Severe immunodeficiency, e.g., hematologic and solid tumors, chemotherapy, congenital 
immunodeficiency or long-term immunosuppressive therapy3, HIV infection with severe 
immunocompromise
• Pregnancy
• Recent (within 11 months) receipt of antibody-containing blood product (specific interval depends on 
product)4
• Receipt of specific antiviral drugs (acyclovir, famciclovir, or valacyclovir) 24 hours before vaccination 
(avoid use of these antiviral drugs for 14 days after vaccination)
HZV2 • Severe immunodeficiency, e.g., hematologic and solid tumors, chemotherapy, congenital 
immunodeficiency or long-term immunosuppressive therapy3, HIV infection with severe 
immunocompromise
• Pregnancy
• Receipt of specific antiviral drugs (acyclovir, famciclovir, or valacyclovir) 24 hours before vaccination 
(avoid use of these antiviral drugs for 14 days after vaccination)
HPV vaccine • Pregnancy
PCV13 • Severe allergic reaction to any vaccine containing diphtheria toxoid
1. For additional information on use of influenza vaccines among persons with egg allergy, see: CDC. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization 
Practices—United States, 2016–17 influenza season. MMWR 2016;65(RR-5):1–54. Available at www.cdc.gov/mmwr/volumes/65/rr/rr6505a1.htm.
2. MMR may be administered together with VAR or HZV on the same day. If not administered on the same day, separate live vaccines by at least 28 days. 
3. Immunosuppressive steroid dose is considered to be daily receipt of 20 mg or more prednisone or equivalent for two or more weeks. Vaccination should be deferred for at least 1 month after discontinuation of 
immunosuppressive steroid therapy. Providers should consult ACIP recommendations for complete information on the use of specific live vaccines among persons on immune-suppressing medications or with immune 
suppression because of other reasons.
4. Vaccine should be deferred for the appropriate interval if replacement immune globulin products are being administered. See: CDC. General recommendations on immunization: recommendations of the Advisory Committee 
on Immunization Practices (ACIP). MMWR 2011;60(No. RR-2). Available at www.cdc.gov/mmwr/preview/mmwrhtml/rr6002a1.htm. 
5. Measles vaccination may temporarily suppress tuberculin reactivity. Measles-containing vaccine may be administered on the same day as tuberculin skin testing, or should be postponed for at least 4 weeks after vaccination.
Table. Contraindications and precautions for vaccines recommended for adults aged 19 years or older*
The Advisory Committee on Immunization Practices (ACIP) recommendations and package inserts for vaccines provide information on contraindications and precautions related to vaccines. Contraindications are conditions 
that increase chances of a serious adverse reaction in vaccine recipients and the vaccine should not be administered when a contraindication is present. Precautions should be reviewed for potential risks and benefits for vaccine 
recipient. For a person with a severe allergy to latex, e.g., anaphylaxis, vaccines supplied in vials or syringes that contain natural rubber latex should not be administered unless the benefit of vaccination clearly outweighs the risk for 
a potential allergic reaction. For latex allergies other than anaphylaxis, vaccines supplied in vials or syringes that contain dry, natural rubber or natural rubber latex may be administered.
Vaccine Contraindications Precautions
All vaccines routinely recommended for adults • Severe reaction, e.g., anaphylaxis, after a previous dose or to a vaccine component • Moderate or severe acute illness with or without fever
Additional contraindications and precautions for vaccines routinely recommended for adults
Contraindications and precautions for vaccines routinely recommended for adults
*  Adapted from: CDC. Table 6. Contraindications and precautions to commonly used vaccines. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices. MMWR 
2011;60(No. RR-2):40–41 and from: Hamborsky J, Kroger A, Wolfe S, eds. Appendix A. Epidemiology and prevention of vaccine preventable diseases. 13th ed. Washington, DC: Public Health Foundation, 2015. Available at www.cdc.
gov/vaccines/pubs/pinkbook/index.html. 
Acronyms of vaccines recommended for adults
HepA hepatitis A vaccine
HepA-HepB hepatitis A and hepatitis B vaccines
HepB hepatitis B vaccine
Hib  Haemophilus influenzae type b conjugate vaccine
HPV vaccine human papillomavirus vaccine
HZV herpes zoster vaccine
IIV inactivated influenza vaccine
LAIV live attenuated influenza vaccine 
MenACWY serogroups A, C, W, and Y meningococcal conjugate 
vaccine
MenB  serogroup B meningococcal vaccine
MMR  measles, mumps, and rubella vaccine
MPSV4  serogroups A, C, W, and Y meningococcal 
polysaccharide vaccine
PCV13  13-valent pneumococcal conjugate vaccine 
PPSV23  23-valent pneumococcal polysaccharide vaccine
RIV recombinant influenza vaccine
Td  tetanus and diphtheria toxoids
Tdap  tetanus toxoid, reduced diphtheria toxoid, and 
acellular pertussis vaccine
VAR varicella vaccine
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